Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes

Diabetes Research and Clinical Practice

Volumn 44, Issue 2, 1999, Pages 107-114

  Takamura, Toshinari ^a   Ando, Hitoshi ^a   Nagai, Yukihiro ^a   Yamashita, Haruhisa ^a   Nohara, Erika ^a   Kobayashi, Ken Ichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Autoimmune diabetes; Multiple low dose streptozotocin; Pioglitazone; PPAR ; Thiazolidinedione

Indexed keywords

NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; HISTOLOGY; INSULITIS; MACROPHAGE ACTIVATION; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PERITONEUM MACROPHAGE; STREPTOZOCIN DIABETES;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; MALE; MICE; STREPTOZOCIN; THIAZOLES; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 0032868391     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(99)00030-3     Document Type: Article

References (30)

1. Foulis A.K. The pathogenesis of β cell destruction in Type I (insulin-dependent) diabetes mellitus. J. Pathol. 152:1987;141-148.
2. Gepts W., LeCompte P.M. The pathology of type I (juvenile) diabetes. yolk B.W., Arquilla E.R. The Diabetic Pancreas. 1985;337-365 Plenum, New York, NY.
3. Kolb-Bachofen V., Epstein S., Kiesel U., Kolb H. Low-dose streptozocin-induced diabetes in mice: electron microscopy reveals single-cell insulitis before diabetes onset. Diabetes. 37:1988;21-27.
4. Rabinovitch A., Suarez-Pinzon W.L., Solensen O., Bleackley C. Inducible nitric oxide synthase (iNOS) in pancreatic islets of non-obese diabetic mice: identification of iNOS expressing cells and relationships to cytokines expressed in the islets. Endocrinology. 137:1996;2093-2099.
5. Takamura T., Kato I., Kimura N. et al. Transgenic mice overexpressing type 2 nitric oxide synthase in pancreatic β cells develop insulin-dependent diabetes without insulitis. J. Biol. Chem. 273:1998;2493-2496.
6. Hofmann C.A., Colca J.R. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care. 15:1992;1075-1078.
7. 2 is a ligand for adipocyte determination factor PPAR-γ Cell. 83:1995;803-812.
8. 2 metabolise binds peroxisome proliferator-activated receptor β and promotes adipocyte differentiation. Cell. 83:1995;813-819.
9. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPAR-γ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8:1994;1224-1234.
10. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR-γ2, a lipid-activated transcription factor. Cell. 79:1994;1147-1156.
11. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391:1998;79-82.
12. Jiang C., Ting A.T., Seed B. PPAR-γ inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-86.
13. Kolb H., Kroncke K.-D. IDDM: lessons from the low-dose streptozotocin model in mice. Diabetes Rev. 1:1993;116-126.
14. Iwakiri R., Nagafuchi S., Kounoue E. et al. Immunohistochemcal study of insulitis induced by multiple low doses of streptozocin in CD-1 mice. Diabetes Res. Clin. Pract. 9:1990;75-82.
15. Like A.A., Rossini A.A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science. 193:1976;415-417.
16. Rossini A.A., Appel M.C., Williams R.M., Like A.A. Genetic influence of the streptozotocin-induced insulitis and hyperglycemia. Diabetes. 26:1977;916-920.
17. Oschilewski M., Schwab E., Kiesel U. et al. Administration of silica or monoclonal antibody to Thy-1 prevents low-dose streptozotocin-induced diabetes in mice. Immunol. Lett. 12:1986;289-294.
18. Andrade J., Conde M., Sobrino F., Bedoya F.J. Activation of peritoneal macrophages during the prediabetic phase in low-dose streptozotocin-treated mice. FEBS Lett. 327:1993;32-34.
19. Tsuji A., Sakurai H. Vanadyl ion suppresses nitric oxide production from peritoneal macrophages of streptozotocin-induced diabetic mice. Biochem. Biophys. Res. Commun. 226:1996;506-511.
20. Linn T., Noke M., Woehrle M. et al. Fish oil-enriched diet and reduction of low-dose streptozotocin-induced hyperglycemia: inhibition of macrophage activation. Diabetes. 38:1989;1402-1411.
21. Beales P.E., Liddi R., Giorgini A.E. et al. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. Eur. J. Pharmacol. 357:1988;221-225.
22. Yoshioka T., Fujita T., Kanai T. et al. Studies on hindered phenol and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J. Med. Chem. 32:1989;421-428.
23. Noguchi N., Sakai H., Kato Y. et al. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis. 123:1996;227-234.
24. Mendola J., Wright J.R. Jr., Lacy P.E. Oxygen free-radical scavengers and immune destruction of murine islets in allograft rejection and multiple low-dose streptozocin-induced insulitis. Diabetes. 38:1989;379-385.
25. Heineke E.W., Johnson M.B., Dillberger J.E., Robinson K.M. Antioxidant MDL 29 311 prevents diabetes in non-obese diabetic and multiple low-dose STZ-injected mice. Diabetes. 42:1993;1721-1730.
26. Ohta M., Nagai Y., Yamashita H., Yoshizawa M., Hisada A., Kobayashi K. Inhibitory effect of troglitazone (CD-045) on cytokine-induced monocyte chemoattractant protein-1 (MCP-1) expression in human mesangeal cells. Diabetologia. 40(Suppl. 1):1997;A434.
27. Grewal I.S., Rutledge B.J., Fiorillo J.A. et al. Transgenic monocyte chemoattractant protein-1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without diabetes. J. Immunol. 159:1997;401-408.
28. Skyler J.S., Marks J.B. Immune intervention. LeRoith D., Taylor S.I., Olefsky J.M. Diabetes Mellitus. 1996;402-408 Lippincott-Raven, Philadelphia, PA.
29. Kobayashi T., Tamemoto K., Nakanishi K. et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care. 16:1993;780-788.
30. Zimmet P.Z., Tuomi T., Mackay I.R. et al. Latent autoimmune diabetes mellitus in adult (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin deficiency. Diabet. Med. 11:1994;299-303.